Amicus brief of over 300 reproductive health researchers supports mifepristone's safety and effectiveness

Amanda Barrow; Cathren Cohen; Jaclyn Serpico; Melissa Goodman; Daniel Grossman; Sarah Raifman; Ushma Upadhyay

doi:10.1111/psrh.12282

Amicus brief of over 300 reproductive health researchers supports mifepristone's safety and effectiveness

Perspect Sex Reprod Health. 2024 Dec;56(4):317-319. doi: 10.1111/psrh.12282. Epub 2024 Jul 29.

Authors

Amanda Barrow¹, Cathren Cohen¹, Jaclyn Serpico¹, Melissa Goodman¹, Daniel Grossman², Sarah Raifman², Ushma Upadhyay²

Affiliations

¹ Center on Reproductive Health, Law, and Policy, University of California Los Angeles, Los Angeles, California, USA.
² Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California San Francisco, Advancing New Standards in Reproductive Health, Oakland, California, USA.

PMID: 39074978
DOI: 10.1111/psrh.12282

Abstract

On January 30, 2024, over 300 researchers filed an amicus brief in FDA v. Alliance for Hippocratic Medicine, a United States (US) Supreme Court case concerning the regulatory status of mifepristone, one of two drugs used in medication abortion. In this Comment we summarize the legal challenge, responses from the FDA and drug manufacturer to these challenges, oral arguments presented before the Court, and the implications of the Court's decision on access to mifepristone in the US. We also summarize the content of the accompanying amicus brief.

Keywords: Food and Drug Administration; abortion; law/legal issues; medication abortion; policy.

Publication types

Editorial

MeSH terms

Abortifacient Agents, Steroidal* / therapeutic use
Abortion, Induced* / legislation & jurisprudence
Female
Humans
Mifepristone* / therapeutic use
Pregnancy
Reproductive Health
Supreme Court Decisions
United States
United States Food and Drug Administration*

Substances

Mifepristone
Abortifacient Agents, Steroidal